Cargando…
Advanced Glycation End Products and Psoriasis
Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and se...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056603/ https://www.ncbi.nlm.nih.gov/pubmed/36992201 http://dx.doi.org/10.3390/vaccines11030617 |
_version_ | 1785016163219013632 |
---|---|
author | Maurelli, Martina Gisondi, Paolo Girolomoni, Giampiero |
author_facet | Maurelli, Martina Gisondi, Paolo Girolomoni, Giampiero |
author_sort | Maurelli, Martina |
collection | PubMed |
description | Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis. |
format | Online Article Text |
id | pubmed-10056603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100566032023-03-30 Advanced Glycation End Products and Psoriasis Maurelli, Martina Gisondi, Paolo Girolomoni, Giampiero Vaccines (Basel) Review Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis. MDPI 2023-03-08 /pmc/articles/PMC10056603/ /pubmed/36992201 http://dx.doi.org/10.3390/vaccines11030617 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Maurelli, Martina Gisondi, Paolo Girolomoni, Giampiero Advanced Glycation End Products and Psoriasis |
title | Advanced Glycation End Products and Psoriasis |
title_full | Advanced Glycation End Products and Psoriasis |
title_fullStr | Advanced Glycation End Products and Psoriasis |
title_full_unstemmed | Advanced Glycation End Products and Psoriasis |
title_short | Advanced Glycation End Products and Psoriasis |
title_sort | advanced glycation end products and psoriasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056603/ https://www.ncbi.nlm.nih.gov/pubmed/36992201 http://dx.doi.org/10.3390/vaccines11030617 |
work_keys_str_mv | AT maurellimartina advancedglycationendproductsandpsoriasis AT gisondipaolo advancedglycationendproductsandpsoriasis AT girolomonigiampiero advancedglycationendproductsandpsoriasis |